Epizyme

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.

Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Epizyme headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $150.1B in funding across 180 round(s). With a team of 101-250 employees, Epizyme is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Epizyme, raised $32.0M. Discover more about their projects, partnerships, and impact on our platform.